Blood Culture Test Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032

The Blood Culture Test Market Size accounted for USD 5.2 Billion in 2022 and is estimated to achieve a market size of USD 11.6 Billion by 2032 growing at a CAGR of 8.5% from 2023 to 2032.

Blood Culture Test Market Highlights

• Global blood culture test market revenue is poised to garner USD 11.6 billion by 2032 with a CAGR of 8.5% from 2023 to 2032
• North America blood culture test market value occupied around USD 1.9 billion in 2022
• Asia-Pacific blood culture test market growth will record a CAGR of more than 10% from 2023 to 2032
• Among product, the consumables sub-segment generated over US$ 2.9 billion revenue in 2022
• Based on technology, the culture-based technology sub-segment generated around 68% share in 2022
• Focus on research and development encourages the introduction of innovative solutions is a popular blood culture test market trend that fuels the industry demand

Blood cultures are microbiological tests used to detect blood-borne infections such as bacteremia and septicemia, which spread through the bloodstream. Normally, the bloodstream is sterile, making detection possible. However, a poorly conducted blood culture can lead to negative effects, including the risks of false venipuncture and false positive results. This occurrence has been observed in over 3% of blood culture cases and can be exacerbated by improper treatment and diagnosis. Bloodstream infections (BSI) significantly impact global health and medical expenses, representing a leading cause of morbidity and mortality. In the US alone, it's estimated that an additional 1 million patients are diagnosed with BSI, costing the healthcare system nearly one billion dollars.

Global Blood Culture Test Market Dynamics

Market Drivers

• Increasing demand for precise diagnostics
• Technological advancements drive innovation in blood culture testing
• Rising incidences of blood-borne infections 
• Growing awareness and adoption of blood culture tests

Market Restraints

• High costs associated with advanced blood culture testing
• Stringent regulatory requirements pose challenges for product approvals
• Limited access to advanced healthcare facilities

Market Opportunities

• Expansion in emerging markets presents untapped growth opportunities
• Development of cost-effective blood culture testing methods 
• Collaborations and partnerships enhance product development and market reach

Blood Culture Test Market Report Coverage

Blood Culture Test Market Insights

The blood testing industry is driven by several factors, including high incidences of blood infections, growing demand for rapid diagnostic testing, expanding aging populations worldwide, rapid advancements in medical technology, increased patient awareness, and the adoption of state-of-the-art technologies. Among the latest technologies for blood culture testing are Multiplex PCR systems, molecular approaches, mass spectrometry, and electric spray ionization. However, market constraints include the high costs associated with advanced blood culture techniques and the absence of adequate refund policies. Additionally, in developing countries or resource-limited nations, insufficient training of medical technicians is expected to hinder revenue growth in the market.

Regulatory authorities have significantly contributed to growth by increasing the approval rate of new products designed for Bloodstream Infections (BSI), including instruments and consumer products. Blood testing is crucial in diagnosing various infections, including bacterial, fungal, and mycobacterial infections. Healthcare professionals utilize several techniques for infection detection, ranging from conventional/manual to automated blood culture methods, which will likely spur increased demand in the near future.

Furthermore, alongside the development of advanced instruments, consumer products, and software, many healthcare companies have ramped up their R&D activities. Investing in research and development to create new products stands as a key strategy for providers to ensure sustained long-term business growth.

The development and production of diagnostic products, including blood cultivation products, may face challenges due to stringent government regulations, potentially impeding market development. Prior to regulatory approval, rigorous trials are conducted for diagnostic products, encompassing instruments, kits, reagents, media, and testing. This process significantly increases manufacturers' costs and leads to launch delays. The marketing of diagnostic products relies heavily on the successful completion of lengthy, expensive, and high-risk clinical trials. Moreover, product retrieval poses another significant challenge for manufacturers, potentially exerting a negative impact on growth.

Blood Culture Test Market Segmentation

The worldwide market for blood culture test is split based on product, technique, technology, application, end use, and geography.

Blood Culture Test Products

• Consumables
  • Bacterial Infections
  • Fungal Infections
  • Mycobacterial Infections
  • Blood Culture Media
    • Aerobic
    • Anaerobic
    • Fungi/Yeast
    • Others
  • Assay, Kits, and Reagents
  • Blood Culture Accessories
• Instruments
  • Bacterial Infections
  • Fungal Infections
  • Mycobacterial Infections
  • Laboratory Equipment
    • Incubators
    • Colony counters
    • Microscopes
    • Gram stainers
  • Automated Blood Culture Systems
• Software & Services
  • Bacterial Infections
  • Fungal Infections
  • Mycobacterial Infections

According to blood culture test industry analysis that, driven by the escalating use of blood culture media, tests, kits, reagents, and associated accessories in diagnostics, consumables emerged as the predominant revenue-generating segment in the blood culture testing market. Additionally, recurrent purchases propel growth in this sector. Forecasts anticipate substantial Compound Annual Growth Rate (CAGR) in the instruments segment, attributed to ongoing product advancements. Automated systems, incubators, and colonies have gained extensive usage in clinics and diagnostic laboratories.

To meet evolving customer needs, diagnostic companies prioritize the development of state-of-the-art products. For instance, bioMérieux, a leading diagnostic company, unveiled its VIRTUO product an advanced blood culture control system for microbial detection attaining a CE mark. The demand for advanced blood culture products is surging due to the rising prevalence of BSI and infectious diseases. Advanced automated systems deliver rapid results, mitigate contamination risks, and ensure highly reliable outcomes.

Blood Culture Test Technique

• Conventional
• Automated

The market distinguishes between conventional and automated technologies. Conventional technology, widely used by hospitals, independent clinical labs, and pathology laboratories, dominated the market in 2022. However, due to technological advancements offering faster and more accurate results and increased R&D investments by manufacturers for new product development, automated blood culture technology is expected to exhibit the highest CAGR during the forecast period.

Companies aim to introduce highly reliable and effective testing solutions using advanced instruments and consumables. For instance, in June 2014, Becton, Dickinson and Company launched the BD BACTEC FX40 and the BD EpiCenter Microbiology Data Management System. The United States, Germany, France, the UK, China, Japan, and India are projected to hold substantial market shares. Factors such as the growing prevalence of infections, improving healthcare infrastructure, and the presence of numerous diagnostic companies are expected to contribute significantly to this growth.

Blood Culture Test Technology 

• Culture-based Technology
• Molecular Technology
  • PCR
  • Microarray
  • PNA-FISH
• Proteomic technology

The market is categorized into culturally-based, molecular, and proteomic technologies. Cultural technology held the largest revenue share in 2022, largely due to its extensive utilization across various laboratories such as hospitals, reference facilities, pathologies, and medical labs. However, the molecular technology segment is projected to exhibit the highest Compound Annual Growth Rate (CAGR) in the blood culture test industry forecast period. This growth is driven by increased R&D investments in manufacturing and the rising incidence of infectious diseases, fostering demand for rapid diagnostic techniques capable of identifying bacterial or fungal infections in blood samples.

The demand for cutting-edge diagnostic technologies like Microarray, PCR, and Peptide Nucleic Acid–PNA-FISH is anticipated to drive market growth. PNA-FISH, offering advantages such as higher accuracy, reduced test times, and enhanced testing specificity, is expected to achieve the highest CAGR during the culture test market forecast period. The necessity for blood culture testing is propelled by the development of healthcare infrastructure and increasing disposable income in the Asia Pacific and MEA regions. Furthermore, increased government initiatives aimed at enhancing healthcare facilities and adopting advanced technologies are expected to further boost the adoption of these tests.

Blood Culture Test Application

• Bacterial Infections
• Fungal Infections
• Mycobacterial Infections

In terms of blood culture test market analysis, the bacterial infections segment dominates the market due to its prevalence and clinical significance. Bacterial infections, ranging from common pathogens to developing antibiotic-resistant strains, drive the majority of blood culture tests. The importance of identifying and treating bacterial illnesses quickly contributes to the popularity of this section. Hospitals, clinics, and laboratories prioritise bacterial infection diagnoses, driving up demand for blood culture tests designed to detect bacterial pathogens quickly and reliably, reflecting the segment's market leadership.

Blood Culture Test End-Use

• Hospital Laboratories
• Reference Laboratories
• Others

The hospital laboratories segment's dominance in the blood culture test market originates from its critical role as the primary site for patient care and diagnosis. As part of immediate patient management, hospital laboratories rely largely on blood culture tests to identify bloodstream infections in a timely manner. Their quick turnaround time and precise results aid in guiding focused treatments. With hospitals at the forefront of healthcare delivery, the necessity for precise and speedy blood culture testing cements the Hospital Laboratories segment's market leadership.

Blood Culture Test Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

The Middle East & Africa

• South Africa
• GCC Countries
• Rest of the Middle East & Africa (ME&A)

Blood Culture Test Market Regional Analysis

North America led in revenues in 2022 due to major health companies like Becton, Dickinson and Company; bioMérieux SA; Thermo Fisher Scientific, Inc.; and Roche Diagnostics. In Europe, market growth is anticipated, particularly in countries like Germany, the United Kingdom, Switzerland, driven by the availability of advanced diagnostic products and well-established health infrastructures. Additionally, increased investment in R&D by manufacturers for new product development is expected to fuel growth.

The forecast period predicts significant growth in Asia-Pacific, attributed to prevalent infectious diseases and developing healthcare infrastructure. Diagnostic companies, particularly in China and India, are expanding their businesses in Asian countries. Factors such as a large target population and rising disposable income contribute to the regional market's growth.

Blood Culture Test Market Players

Some of the top blood culture test companies offered in our report includes Abbott Laboratories, Bayer AG, bioMérieux SA, Bruker Corporation, CytoTest Inc., Danaher Corporation, Devyser, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Mikroscan Technologies, Inc., Novartis AG, Siemens Healthcare GmbH, Terumo Corporation, Thermo Fisher Scientific Inc., ZenTech S.A., and ZeptoMetrix Corporation.